Members Login
 

The WHO Early Release Guideline on ARV and PrEP

were published on September

30th, 2015 and can be

found here:

 Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

JIAS Special Issue: PrEP Implementation Science: State-of-the-Art and Research Agenda, organized by NEMUS (published July 2015).

 Please visit Nemus´Youtube channell

 

Follow us in Facebook

 

and Twiter

Resources

Up

Documents

Here you will find guidance documents, primary study reports, editorials and commentaries, and other documentation relating to ARV based HIV prevention relevant to countries or a the global level.

GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV
Las Promesas y Desafíos de la Profilaxis Pre-Exposición dentro del Paradigma Emergente de la Prevención Combinada del VIH

A continuación pueden descargar el texto de la Introducción del JAIDS Special Issue traducida al castellano

ECDC Comment on PrEP - slides
South African Guidelines for PrEP
Uptake of PrEP for HIV slow among MSM
Recommendations for use of ARV drugs in HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the US
PrEP for the Prevention of HIV Infection in the US - Providers Supplement
PrEP for the Prevention of HIV Infection in the US
Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco
WHO Guidelines for Treatment as Prevention of HIV and TB
WHO Guidance on PEP, 2007
WHO Guidance of PMTCT of HIV
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

These WHO consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and treatment. Behavioural, structural and biomedical interventions that do not involve the use of ARV drugs are not covered in these guidelines.

 

Annexes to Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV

These WHO recommendations have been developed specifically to address the daily use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection. This prevention approach is known as pre-exposure prophylaxis.

At this stage evidence is available from studies with two groups: men and transgender women who have sex with men; and serodiscordant heterosexual couples. In parallel, WHO also is preparing new recommendations on the use of antiretroviral drugs in people living with HIV to prevent transmission of infection.

 

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV

These WHO recommendations have been developed specifically to address the daily use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection. This prevention approach is known as pre-exposure prophylaxis.

At this stage evidence is available from studies with two groups: men and transgender women who have sex with men; and serodiscordant heterosexual couples. In parallel, WHO also is preparing new recommendations on the use of antiretroviral drugs in people living with HIV to prevent transmission of infection.